NGNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Neurogene Inc (NGNE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The FDA Breakthrough Therapy designation for NGN-401 is a strong positive catalyst, and the stock is experiencing a significant pre-market price surge of 28.10%. While financial performance is weak, the company's potential in the biotech space and the recent analyst rating with a $50 price target make it a compelling long-term opportunity.
The MACD is positive at 0.367 and expanding, indicating bullish momentum. The RSI is neutral at 67.599, and moving averages are converging, suggesting no immediate overbought or oversold conditions. The stock is trading above its pivot level of 18.271, with resistance levels at 19.817 and 20.771, indicating potential for further upside.
The FDA granted Breakthrough Therapy designation to NGN-401 for Rett syndrome, which is a significant positive development. Analyst Patrick Dolezal initiated coverage with an Outperform rating and a $50 price target, indicating strong growth potential.
Weak financial performance in the latest quarter, with a net income of -$20.95M and a decline in EPS by -16.81% YoY. Gross margin dropped to 0, indicating no profitability.
In Q3 2025, Neurogene reported no revenue growth, a net income loss of -$20.95M (up 3.64% YoY), and a decline in EPS to -0.99 (-16.81% YoY). The gross margin dropped to 0, reflecting poor financial health.
LifeSci Capital analyst Patrick Dolezal initiated coverage with an Outperform rating and a $50 price target, indicating strong confidence in the stock's future performance.
